PHARMACEUTICAL PREPARATIONS
Lakewood-Amedex Biotherapeutics Inc. Common Stock
LABT
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
No ratio data was found for LABT.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Revenue | $0 |
| Cost of revenue | $0 |
| Gross profit | $0 |
| Selling, general and administrative | $3.29M |
| Research and development | $503.02K |
| Total operating expenses | $3.79M |
| Operating income | -$3.79M |
| Interest expense | -$10.63K |
| Income before taxes | -$3.77M |
| Income taxes | $0 |
| Net income | -$3.77M |
| Net income attributable to common shareholders | -$3.9M |
| EBITDA | -$3.79M |
| Basic earnings per share | -$2.75 |
| Diluted earnings per share | -$2.75 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
| Execution date | Split ratio | Event type |
|---|---|---|
| Jun 22, 2026 | 1-for-10 | reverse split |